PF-03758309 |CAS 898044-15-0|DC Chemicals

Cas No.:	898044-15-0
Chemical Name:	PF-3758309
Synonyms:	PF-3758309;N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide;PF 3758309;PK459EA5I2;(S)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-3-((2-methylthieno[3,2-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide;N-((1S)-2-(Dimethylamino)-1-phenylethyl)-6,6-dimethyl-3-((2-methylthieno(3,2-d)pyrimidin-4-yl)amino)-4,6-dihydropyrrolo(3,4;PF-03758309;N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (ACI);N-[(1S)-2-(Dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide;PF 03758309
SMILES:	N(C1N=C(C)N=C2C=CSC=12)C1=NNC2C(N(CC1=2)C(=O)N[C@@H](C1C=CC=CC=1)CN(C)C)(C)C
Formula:	C₂₅H₃₀N₈Os
M.Wt:	490.623702526093
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

An orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer cell growth. PAK4, a serine/threonine kinase belonging to the p21-activated kinase (PAK) family, is often upregulated in a variety of cancer cell types and plays an important role in cancer cell motility, proliferation, and survival. For the detailed information of PF-03758309, the solubility of PF-03758309 in water, the solubility of PF-03758309 in DMSO, the solubility of PF-03758309 in PBS buffer, the animal experiment (test) of PF-03758309, the cell expriment (test) of PF-03758309, the in vivo, in vitro and clinical trial test of PF-03758309, the EC50, IC50,and Affinity of PF-03758309, Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC7059	PF-03758309	PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity.